Skip To Main Content
Robert Cameron on Muck Rack

Robert Cameron

As seen in: Medium, Nature, Frontiers, MDPI, The Conversation, Science Magazine, U.S. Army, Royal Society of Chemistry, Cell Press, WDIV-TV (Detroit, MI) and
Writer, editor, photographer, ライター、編集者、写真家、翻訳者。Runner, Japanese studier, cooker, player of guitar, bass, ukulele

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

@acyn.bsky.social on Bluesky

|
By Robert Cameron, Xenon Stern
| bsky.app
This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is. Learn more about Bluesky at bsky.social and atproto.com. Acyn acyn.bsky.social did:plc:iu4j537hox5huj4bwnwgub4z Warner on CBS: I was embarrassed that the president went before our country and networks like yours carried this as news as opposed to a rehash of falsehoods. It is incumbent upon you and any responsible journalist to pushback on this.
Open in Who Shared Issue with article?

Self-consistent numerical simulations for the formation and dynamics of solar prominences

|
By Robert Cameron, Sami K. Solanki, Damien Przybylski, Lisa-Marie Zessner
| Nature Verified
Abstract Solar prominences are cool and dense plasma structures floating in the hot solar corona. They are ubiquitous features in the solar atmosphere, but their formation mechanism is still unclear. Here we perform comprehensive fully three-dimensional numerical simulations of prominence formation including the physics necessary to describe all atmospheric layers of the sun. With appropriate initial conditions for the magnetic field, solar prominences form self-consistently in the simulations.
Open in Who Shared Issue with article?

Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges

|
By Faith Abodunrin, Robert Cameron, Waqas Haque, Christine M. Bestvina, Marina C. Garassino
| Frontiers
Abstract Systemic treatment for resectable early-stage non-small cell lung cancer (NSCLC) has historically consisted of chemotherapy, with limited efficacy and substantial toxicity. Immune checkpoint inhibitors (ICI) have found increasing use in neoadjuvant, adjuvant, and perioperative settings. In this review, we summarize major clinical trials using ICI in the adjuvant, neoadjuvant, and perioperative settings.
Open in Who Shared View Duplicates (10) Issue with article?
See all 773 licensed articles (779 Total)